

11TH ANNUAL

WORLD
OrphanDrug

Congress USA 2021

August 25–27, 2021

Gaylord National Harbor Hotel, Oxon Hill, Maryland USA



Featuring:

**Rare
Disease** **Advocacy**
WORLD USA 2021

Pitch & Partner
2021

Advanced **Therapies**
Rare Disease 2021

terrapinn.com/orphandrugsusa



KEYNOTE SPEAKER

Janet Woodcock

Acting Commissioner,
Food and Drug Administration



KEYNOTE SPEAKER

Suneet Varma

Global President, Rare Disease, Pfizer

OUR STORY

The World's Most Important Orphan Drug & Rare Disease Event

The 11th annual World Orphan Drug Congress USA is back — and in-person — with our most comprehensive program and inclusive gathering of rare disease stakeholders yet!

Becoming the largest rare disease and orphan drug conference globally has allowed us to bring together leading industry, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers. The World Orphan Drug Congress USA allows attendees to meet, brainstorm and dialogue on ways to advance orphan drug development and improve access to life-saving therapies.

Over 1,500 attendees from 50+ countries will gather in Oxon Hill, Maryland on August 25th-27th for the 11th edition of World Orphan Drug Congress USA!

Our conference has become the industry defining meeting on Advanced Therapies for rare diseases, featuring discussions on clinical development, manufacturing and commercialization of cell and gene therapies. It also is the annual gathering for artificial intelligence, digital health solutions, and drug development platforms transforming the rare disease industry!

We look forward to safely gathering in-person this August 25th-27th in Oxon Hill, MD. For updated COVID-19 safety protocols, please visit our website: terrapiinn.com/orphandrugsusa

STATS & FEATURES



200
SPEAKERS



50+
COUNTRIES



13
STREAMS OF
CONTENT



2000+
1-2-1 MEETINGS



1500+
ATTENDEES



100
SPONSORS &
EXHIBITORS

For Sponsorship and Exhibition Opportunities: justin.franks@terrapiinn.com
For Speaking Opportunities: claire.murphy@terrapiinn.com



OUR WORLD-CLASS CONFERENCE FEATURE THE FOLLOWING THEMES:



PATIENT DATA




NEXT GENERATION
THERAPIES



PAYERS



CLINICAL DEVELOPMENT
AND REGULATORY



COMMERCIAL




RARE DISEASE ADVOCACY
WORLD



GLOBAL MARKET &
PATIENT ACCESS



PRICING &
REIMBURSEMENT




PITCH & PARTNER



ADVANCED THERAPIES –
MANUFACTURING



ADVANCED THERAPIES –
CLINICAL DEVELOPMENT



RARE ONCOLOGY



ADVANCED THERAPIES –
COMMERCIALIZATION



DIGITAL HEALTH &
ARTIFICIAL INTELLIGENCE



DIAGNOSIS



DISCOVERY



terrapinn.com/orphandrugsusa



KEYNOTE SPEAKER

Shannon Resetich

Global Franchise Head,
Rare Diseases, Sanofi Genzyme



KEYNOTE SPEAKER

John Crowley

Chairman & CEO,
Amicus Therapeutics

200+ SPEAKERS INCLUDING



Janet Woodcock
Acting Commissioner, **Food and Drug Administration (FDA)**



Peter Marks
Director, Center for Biologics Evaluation and Research (CBER), **Food and Drug Administration (FDA)**



Shannon Resetch
Global Franchise Head, Rare Diseases, **Sanofi Genzyme**



Suneet Varma
Global President of Rare Disease, **Pfizer**



Anne Pariser
Director, ORDR, NCATS, **National Institutes of Health (NIH)**



Nancy Mendelson
Chief Medical Officer, Complex Health Solutions, **UnitedHealthcare**



Jeremy Levin
Chairman and Chief Executive Officer, Chairman, BIO, **Ovid Therapeutics**



John Crowley
Chairman & CEO, **Amicus Therapeutics**



Rachelle Jacques
Chief Executive Officer, **Enzyvant**



David Lennon
President, **Novartis Gene Therapies**



Michael Boyle
President and Chief Executive Officer, **Cystic Fibrosis Foundation**



Geoff MacKay
Chief Executive Officer, **AVROBIO**



Doug Kerr
Chief Medical Officer, **Generation Bio**




Rachele Hendricks-Sturup
Health Policy Lead, **Future of Privacy Forum**



Avril Daly
Vice Chair EURORDIS, CEO, **Retina International**



Alexander Natz
Secretary General, **European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)**



Vikram Karnani
Executive Vice President, President, International, **Horizon Therapeutics**



Phillip Brooks
Program Director, NCATS, **National Institutes of Health (NIH)**



Gianluca Pirozzi
Senior Vice President, Head of Clinical Development and Translational Sciences, **Alexion Pharmaceuticals, Inc.**



Luc Boileau
Président-directeur general, **INESSS**



James Miskin
Chief Technical Officer, **Oxford Biomedica**



Heidi Bjornson-Pennell
Patient Engagement Strategist, **Chan Zuckerberg Initiative**



Azadeh Golipour
SVP, CMC and Manufacturing, **AVROBIO**



Fred Chereau
Chief Executive Officer, **LogicBio**



Steven Peskin
Executive Medical Director Population Health, **Horizon Blue Cross Blue Shield - New Jersey**



Jason Slingsby
Chief Business Officer, **Oxford Biomedica**



Nick Li
Global and US Market Access Lead, **uniQure**



Simon Frost
CEO & Co-Founder, **Tiber Capital Group**



Tamanna Roshan Lal
Co-Director, Lysosomal Storage and Treatment Program, Rare disease Institute, Metabolic Geneticist, **Children's National Medical Center**



Andrew Lo
Charles E. and Susan T. Harris Professor, **Massachusetts Institute of Technology (MIT)**



Bob Zambon
Senior Director, R&D Data Science Strategy & Innovation, **Janssen Research & Development**



Melissa Haendel
Director of the Center for Data to Health, Professor, Medical Informatics and Clinical Epidemiology, Director, Translational Data Science, **Oregon Health & Science University**



Ashish Sagrolikar
EVP & Chief Commercial Officer, **Zogenix**



Francis Arickx
Head of the directorate Reimbursement of Medicines and Pharmaceutical Policy, **National Institute for Health and Disability Insurance (NIHDI RIZIV/INAMI)**



Ulrich Thienel
Chief Executive Officer, **ReAlta Life Sciences**



Amira Awada
Director, Financial And Legal, **Instituto Vidas Raras**



John Walter
Chief Executive Officer, **Foundation for Prader Willi Research**



David Young
Chairman and CEO, **Processa Pharmaceuticals**



Alba Ancochea Diaz
Chief Executive Officer, **FEDER**



Scott Dorfman
Chief Executive Officer, **Odyia Therapeutics**



Craig Malzahn
VP, Technical Operations, **REGENXBIO**



Stacey Frisk
Global Policy, Government & Patient Affairs, **Sarepta Therapeutics**



Joel Schneider
Chief Technology Officer, **Solid Biosciences Inc.**



Christina Hartman
Senior Director of Advocacy, **The Assistance Fund**



Alexander Cole
Executive Director, Global Head Epidemiology, **Alexion Pharmaceuticals, Inc.**



Amanda Moore
Chief Executive Officer, **Angelman Syndrome Foundation**



Bryce Waldman
Manager, Strategy And Market Development, **Rady Children's Institute for Genomic Medicine**



Panna Sharma
President & Chief Executive Officer, **Lantern Pharma**



Graham T. Dempsey
Chief Scientific Officer, **Q-State Biosciences**



Scott T. Williams
Global Public Affairs Head, Rare Diseases and Rare Blood Disorders, Sanofi Genzyme Global Public Affairs, **Sanofi Genzyme**

200+ SPEAKERS INCLUDING



Pamela Gavin
Chief Strategy Officer,
NORD



Daniel Curran
Head, Rare Genetics &
Hematology Therapeutic
Area, **Takeda
Pharmaceuticals**



Paul Aliu
Head Global Governance
Office, Novartis Chief
Medical Office (CMO),
Novartis



**Alison Bateman-
House**
Assistant Professor, Division of
Medical Ethics, **NYU Grossman
School of Medicine**



Annie Kennedy
Chief of Policy and
Advocacy, **EveryLife
Foundation for Rare
Diseases**



Mark Trusheim
Strategic Director, **MIT
NEWDIGS**



Derek Adams
Chief Technology &
Manufacturing Officer,
bluebird bio



David Bettoun
Vice President Discovery
and Non-Clinical R&D,
**Larimar Therapeutics
Inc.**



James Mullen
Chairman, President, Chief
Executive Officer, **Editas
Medicine**



Karen Aiach
Founder, Chairman and
CEO, **Lysogene**




Ken Kengatharan
Managing General Partner,
Atheneos Ventures



Lovena Chaput
SVP, Americas, Commercial,
Astellas Gene Therapies



Gurdyal Kalsi
Chief Medical
Officer, **Asklepiion
Pharmaceuticals**



Rashida Karmali
CEO, **Tactical
Therapeutics Inc**



Jeffrey Strovel
Chief Executive Officer,
Veralox Therapeutics



Pushkal Garg
Chief Medical
Officer, **ALNYLAM
PHARMACEUTICALS**



Rebecca Derwin
Director, Early Commercial
Strategy, **Regenxbio, Inc.**



Daniel Jackson
Global Head of Market
Access Policy, **UCB**



Emily McGinnis
Chief Patient Officer and
Head of Government Affairs,
Taysa Gene Therapies



Scott Gray
President and CEO,
Clinccierge



Linn Parrish
Senior Director, R&D Health
Equity & Patient Affairs,
Takeda Pharmaceuticals



Ellen Weiss
Vice President of Business
Development, **PCM Trials**



Steven Cummings
Executive Director, San Francisco
Coordinating Center, **California
Pacific Medical Center
Research Institute**



Lili Peng
Associate Director, External
Innovation Analytics, **Biogen**



Anne Cropp
Chief Scientific Officer,
Early Access Care, LLC



Sean McAuliffe
Chief Commercial Officer,
Taysha Gene Therapies



Denise Scots-Knight
Chief Executive Officer, **Mereo
Biopharma**



Dylan Simon
Newborn Screening and
Diagnostics Policy Manager,
**EveryLife Foundation for
Rare Diseases**



Mo Heidaran
Vice President, Regulatory
Consulting, **Parexel**



Lucas Kempf
Vice President, Technical,
Parexel



Sarah Glass
Global Head of Rare
Diseases, **Parexel**



Pablo Botas
CEO & Head of Science,
Foundation 29



Gillian Hooker
Past-President, **National
Society of Genetic
Counselors (NSGC)**



Andrew Udell
President of North America,
Commercial, **Calliditas
Therapeutics**



Eric David
CEO, Gene Therapy,
BridgeBio



Ali Mohamadi
Executive Director, Patient
and Medical Alliances,
Vertex Pharmaceuticals



Shirley Bachman
Vice President, US Market
Access, **Alnylam**



**Amanda
Finlayson**
Associate Director of Patient
Strategy, **ClinEdge**



Charlie Small
Associate Director of
Integrated Trial Solutions,
ClinEdge



Dan Donovan
Founder & CEO, **rareLife
solutions**



Kristin Gabor
Research Scientist,
RhoWorld



Joseph Watson
Associate Director,
Regulatory Strategy,
RhoWorld



**Brigitte Tippin-
Davis**
Chief Scientific Officer,
**Ambry Genetics, A
Konica Minolta Company**



Chad Forinash
Senior Director Pharmacy
& Clinical Services,
PharmaCord



Alison Skrinar
Vice President, Clinical
Outcomes Research and
Evaluation, **Ultragenyx
Pharmaceutical inc.**



Chris Jones
Partner, **iTakeControl, a
Red Nucleus Company**



Scott Bergeron
Partner, **iTakeControl, a
Red Nucleus Company**



Scott Schliebner
Senior Vice President,
Scientific Affairs and
Therapeutic Expertise, **PRA**



Joseph Zabinski
Senior Director, AI &
Precision Medicine, **OM1**



Jess Conicelli
Executive Director, Strategic
Development, Rare, Orphan,
& Pediatric Diseases,
Synteract

2021 AGENDA AT A GLANCE

PRE-CONFERENCE | SEMINAR & WORKSHOP DAY

WEDNESDAY, AUGUST 25TH

Payers Seminar

Next Gen Seminar

Patient Data Seminar

MORNING

Sponsored Workshop A

MORNING

Sponsored Workshop B

AFTERNOON

Sponsored Workshop 1

AFTERNOON

Sponsored Workshop 2

MAIN CONFERENCE DAYS | OVERVIEW

STREAM 1

STREAM 2

STREAM 3

STREAM 4

STREAM 5

STREAM 6

DAY 1

THURSDAY, AUGUST 26TH

Clinical Development &
Regulatory

Rare Disease Advocacy
World

Pricing & Reimbursement

Advanced Therapies
Clinical Development

Ai & Digital Health

Rare Oncology

DAY 2

FRIDAY, AUGUST 27TH

Commercialization

Diagnosis

Global Market &
Patient Access

Advanced Therapies
Manufacturing &
Commercial

Drug Discovery

Pitch & Partner



TOPIC AREAS & WHO YOU'LL MEET

 CLINICAL DEVELOPMENT & REGULATORY	 RARE DISEASE ADVOCACY WORLD	 ADVANCED THERAPIES CLINICAL	 PRICING & REIMBURSEMENT	 AI & DIGITAL HEALTH	 PITCH AND PARTNER
WHO ATTENDS					
Pharma, biotechs - VP Clinical Development - Chief Medical Officer - Chief Scientific Officer - Regulatory Affairs - President, Head of Rare Diseases	Pharma, biotechs - Chief Patient Officer - VP Patient Advocacy - Medical Affairs - Patient Engagement Patient Advocacy Groups	Pharma, biotechs - VP Gene Therapy - Chief Medical Officer - Chief Manufacturing Officer - Chief Scientific Officer - VP Manufacturing & Technical Operations	Pharma, biotechs - Chief Executive Officer - VP, Head of Market Access - VP, Head of Pricing and Reimbursement - VP of Health Economics/HEOR - VP of HTA - Head of Value Demonstration - VP, Evidence and Data - Payers (public and private) - Government & Regulatory agencies	Pharma, biotechs - Chief Data Officer - Chief Technology Officer - Chief Operating Officer - VP, Analytics - Head of Innovation - Head of Digital Hospitals and healthcare centers Payers	Pharma, biotechs - CEO - Presidents - Chief Business Officer - VP Business Development - VP External Innovation - VP R&D Venture Capital Firms Grant Agencies (Public and Private) Licensing pharma
TOPIC AREAS:					
- Patient centric clinical development - Clinical trial design - Real World Evidence in clinical development - Expanded Access Programs / Managed Access Programs	- Patient Data - Patient Registries & Patient Reported Outcomes (PROs) - Evolving role of patient groups in R&D - Genetic testing & diagnosis - Advocacy & Policy - Setting up patient groups - Industry collaboration	- Gene therapy development - Cell therapy development - Translational science and path to clinical trials - Regulation	- Advanced therapies pricing & reimbursement - Real World Evidence - Health Technology Assessment - Value Based Assessment - Next generation pricing and innovative pricing models	- AI in drug discovery - Patient identification - Data analytics - Data collection through wearables and applications	- Advanced therapies investment - Risk assessment - Partnering and co-development opportunities - Funding - Accelerating orphan drug development - Successful case studies
WHO SHOULD SPONSOR:					
- Contract Research Organizations (CROs) - Contract Development and Manufacturing Organizations (CDMOs) - Clinical Trials Services - Home Clinical Trials - Patient Recruitment & Identification - Regulatory Consulting	- Pharma & biotechs - Research Institutions - Patient Registries - Patient Engagement Platforms - Genetic Testing providers - Genomic Sequencing Platforms - Diagnostics	- Advanced therapies pharma & biotechs - Gene Editing biotechs - Contract Research Organizations (CROs) - Clinical trial design	- PRO consultancies and PRO technology providers - Value communication organizations - Pricing & Reimbursement consulting firms - HEOR service providers - Patient registries and database providers	- Artificial Intelligence platforms - Patient identification solutions - Machine learning - Data analytics - Wearable technology - Digital Health Apps - Patient registries	- Advanced therapies investment - Risk assessment - Partnering and co-development opportunities - Funders



TOPIC AREAS & WHO YOU'LL MEET

 COMMERCIAL	 DIAGNOSIS	 ADVANCED THERAPIES MANUFACTURING & COMMERCIAL	 GLOBAL MARKET ACCESS	 NEW DISCOVERY	 RARE ONCOLOGY
WHO ATTENDS					
Pharma, biotechs - Chief Commercial Officer - VP Commercial Operations - VP of Marketing - VP Medical Affairs	Pharma, biotechs - Presidents & Heads of Patient Diagnosis Programs - R&D Strategic Alliance Rare Disease advocacy organizations - Newborn Screening	Pharma, biotechs - Chief Operating Officer - Chief Manufacturing & Technology Officer - VP Technical Operations - VP of CMC - VP Manufacturing - VP of Process Development - VP of Quality Control	Pharma, biotechs - VP Market Access - Pricing and Reimbursement - Chief Commercial Officer - International Business Regulators Government - Ministry of Health - Policy makers	Pharma, biotechs - Heads of Discovery - VP Clinical Development - Chief Medical Officer - Chief Scientific Officer - Regulatory Affairs - President, Head of Rare Diseases	Pharma, biotechs - VP Cell Therapy - Head of Oncology - Head of Immunotherapy - Chief Medical Officer
TOPIC AREAS:					
- Business models - Forecasting and Epidemiology - Global expansion and internationalization - Business development	- Genetic counselling - Industry partnerships - Genomics - Newborn Screening - Access & Reimbursement of testing	- Process development - Outsourcing - Viral vector development - Manufacturing efficiency and capacity - Analytical development - Quality Control	- Market entry strategies - Stakeholder collaboration for market access - Real World Evidence - Improving access - International regulation	- Discovery platforms - Artificial Intelligence & Machine Learning applications - Small molecule development - Scientific innovations - Collaborations	- Diagnosis - Biomarker R&D - CAR-T development - Advocacy and patient voice - Clinical development and commercialization
WHO SHOULD SPONSOR:					
- Specialty Pharmacy - Logistics, Supply Chain, 3PL - Strategic Consulting - Real World Evidence - Forecasting and Epidemiology - Marketing, Communications Agency	- Genetic testing companies - Genetic counselling consulting - Genomics companies - Newborn screening providers	- Process development - Outsourcing - Viral vector development - Manufacturing efficiency and capacity - Analytical development	- Market entry strategies - Stakeholder collaboration for market access - Real World Evidence - Improving access - International regulation	- Drug discovery companies - Artificial Intelligence and Machine Learning applications - Predictive analytics platforms - Contract Research Organizations (CROs)	- Immunoncology pharma and biotechs - Contract Manufacturing Organizations (CMOs) - Contract Research Organizations (CROs) - Genomic/DNA sequencing
 PAYERS SEMINAR On this seminar, payers from around the world will discuss approaches and strategies to improve pricing & reimbursement in rare diseases, including innovative pricing schemes and optimization of value-based assessments.	 NEXT GEN THERAPIES SEMINAR Learn about novel pipelines, approaches and candidates on the Next Generation Therapies Seminar, where someday these technologies and therapies could be the common place to treat rare diseases				 PATIENT DATA SEMINAR When developing therapies for rare and ultra-rare diseases the value of patient data is immensurable. Though patients and their families are usually willing to share their data to advance research being their individual causes, issues with data privacy, ownership, consent and handling are still a big hurdle impeding the progress of utilizing data to identify patients, shorten the time for an accurate diagnosis, build disease knowledge, expedite R&D, and enhance access to available therapies.





EDUCATE

Present new technology and ideas WITH a 20min breakout presentation



MARKETING

Build brand awareness WITH your company logo on event collaterals and signage



BUSINESS DEVELOPMENT

Meet 1-on-1 with your prospects and clients WITH 1-2-1 networking meetings



THOUGHT LEADERSHIP

Be seen as a leader or expert in the field WITH roundtable moderation

SPONSORSHIP OPPORTUNITIES



PRE-CONFERENCE WORKSHOP
\$30,000 USD

Pre-Conference workshop to be held on the afternoon of August 25th. Topics to be chosen by sponsor.



MOBILE APP
\$30,000 USD

Exclusive to one sponsor. On-site SMS messaging and branding rights to networking app.



WELCOME PARTY RECEPTION
\$20,000+ USD

Evening before Day 1. Sponsor responsible for cost of food, beverage, & venue.



NETWORKING LOUNGE
\$20,000+ USD

Exclusive to one sponsor. Branding in the expo hall. Sponsor responsible for furnishing space.



HEADSHOT STUDIO
\$15,000+ USD

Exclusive to one sponsor. Sponsor responsible for cost of photographer and associated fees. to be placed on racks at registration for all attendees.



TOTE BAGS
\$10,000 USD

Exclusive to one sponsor. Sponsor responsible for cost of production of totes and shipping.



HOTEL KEYCARDS
\$5,000+ USD

Exclusive to one sponsor. Sponsor responsible for cost of production and hotel service.



MAIN COCKTAIL RECEPTION
\$30,000+ USD

Main reception following Day 1. Sponsor responsible for cost of food, beverage, & venue.



REGISTRATION
\$25,000 USD

Includes branded desks, directional signage, floor clings, and listed as exclusive sponsor on agenda and floorplan.



LANYARD
\$20,000+ USD

Exclusive to one sponsor. Sponsor responsible for cost of lanyard production.



WIFI
\$15,000 USD

Exclusive to one sponsor. Custom network name and password.



TRACK SPONSOR
\$10,000 USD

Exclusive to one sponsor per track. Branding on podium, signage, agenda, floorplan. Moderator from your company.



PPE BRANDING
\$10,000 USD

Branded masks, hand sanitizer, hand sanitizer stations. Included on floor clings promoting social distancing. Sponsor responsible for cost of merchandise and shipping.



NETWORKING BREAK
\$5,000 USD

30 sec ad shown in breakout rooms and app.

SPONSORSHIP PACKAGES


BENEFITS	1 LEFT	1 LEFT	GOLD	SILVER	BRONZE	EXHIBITOR
	TITLE	PLATINUM				
Keynote plenary	1 x 20min in plenary	1 x 20min in plenary				
Case study or Workshop or Panel	1 x 20min in track		1 x 20min in track OR 1 x 4hs workshop on pre-conference	1 x 3hs workshop on pre-conference OR 1 x Panelist OR Chairperson		
Roundtable	1 x 1 hour Roundtable				1 x 1 hour Roundtable OR 1 x 20min seminar presentation	
White Paper Release through	eblast Blog Newsletter Social Media	eblast Blog Newsletter Social Media	eblast Blog Newsletter Social Media			
Exhibit space (SQF)	240 (12x20)	240 (12x20)	120 (12x10)	60 (6x10)	60 (6x10)	60 (6x10)
Branding	Lanyards, Advert	WiFi	Hotel Key Cards (other options available)	Networking lounge, notepads & pens		
Staff Passes	10	8	5	4	3	2
Guest Passes (clients)	7	5	3	2		
1-2-1 Meetings	10	7	5			
Investment (in USD)	\$60,000	\$40,000	\$30,000	\$20,000	\$12,500	\$7,500



For Sponsorship and Exhibition Opportunities: justin.franks@terrapinn.com

For Sponsorship and Exhibition Opportunities: justin.franks@terrapinn.com





CALLING PATIENT ADVOCATES

Complimentary passes available for patient advocacy groups.
Offer is limited to a waived registration fee.

To apply, contact:

Claire Murphy
T: +1 646 619 1784
E: Claire.murphy@terrapinn.com

Each year the World Orphan Drug Congress gathers 200+ individual rare disease advocacy organizations.

OFFICIAL PARTNERS INCLUDE



National Organization for Rare Disorders
(NORD)



EURORDIS



Rare Disease International

TERRAPINN

Our full service app allows you to manage your time efficiently and effectively at the event, while ensuring you meet all the right people.

The app will go live 3 weeks before the event. At that time, you will receive an email with your personalized login.

The app is available on desktop as well as the app store.

NETWORKING APP



DIRECT MESSAGING / 1-2-1 MEETINGS

You can view and message speakers, sponsors and attendees to set up on site meetings & share content leading up to & at the event.

Scheduled meetings will take place in the networking zone at a reserved table.



AGENDA

Use the app to view the most up to date agenda & highlight the sessions you want to attend. You can create your own personal schedule!



SOCIAL MEDIA

Connect your LinkedIn, customize your profile and share relevant content with your social network.



LIVE EVENT NOTIFICATIONS

During the event, you will be notified of any changes you need to be aware of.



CONTACTLESS BUSINESS CARD EXCHANGE

Scan someone's QR code, bar code, or business card to instantly save contact information.




terrapinn.com/orphandrugsusa

MEET IN-PERSON

After a long year of virtual meetings, we're excited to get back to in-person networking. After you set up your meetings through the networking app, you'll head over to our designated networking tables where you'll stay socially distanced for a safe face-to-face meeting.

Please note, our attendee's health and safety is our first priority. The event is mask mandatory and will be handshake free.



Contact justin.franks@terrapinn.com to learn about additional pre-confirmed in-person meetings and networking support.



2021 SPONSORS

PLATINUM SPONSORS



GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS



EXHIBITORS

